Table 3. Cell cycle distribution of 16HBE with knockdown of SELENBP1 and controls after repeated treatment with 1 µm B[a]P or DMSO for 18 weeks.

Cell lines	Number of cell (%)
	G0/G1	S	G2/M
16HBE+DMSO	70.02±4.67	18.58±3.48	11.39±1.63
16HBE/pLKO.1+DMSO	69.10±3.51	19.64±2.87	11.25±1.65
16HBE/pLKO.1-SELENBP1-shRNA+ DMSO	65.79±3.59	21.96±2.58	12.25±2.22
16HBE+ B[a]P	67.94±2.15	19.10±2.44	12.96±2.13
16HBE/pLKO.1+ B[a]P	67.25±4.20	19.64±2.58	13.11±1.81
16HBE/pLKO.1− SELENBP1-shRNA+ B[a]P	50.56±5.24*	35.75±4.49*	13.69±1.55

^* P<0.05 by T-test, 16HBE/pLKO.1-SELENBP1-shRNA+B[a]P vs. 16HBE/pLKO.1+B[a]P, 16HBE+ B[a]P, and 16HBE/pLKO.1-SELENBP1-shRNA+B[a]P vs. 16HBE +DMSO.